Statistics

RUNA digital repository

	Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer	8

Select a period of time:

	Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer	6

	Views
United States	6

	Views
Ashburn	2
Boardman	1